```
<!--StartFragment-->RESULT 3
US-10-097-340-282
; Sequence 282, Application US/10097340
; Publication No. US20030087250A1
; GENERAL INFORMATION:
;  APPLICANT: John MONAHAN
;  APPLICANT:  Manjula GANNAVARAPU
;  APPLICANT:  Sebastian HOERSCH
;  APPLICANT:  Shubhangi KAMATKAR
;  APPLICANT:  Steve G. KOVATS
;  APPLICANT:  Rachel E. MEYERS
;  APPLICANT:  Michael MORRISEY
;  APPLICANT:  Peter OLANDT
;  APPLICANT:  Ami SEN
;  APPLICANT:  Peter VEIBY
;  APPLICANT:  Gordon B. MILLS
;  APPLICANT:  Robert C. BAST, Jr.
;  APPLICANT:  Karen LU
;  APPLICANT:  Rosemarie SCHMANDT
;  APPLICANT:  Xumei ZHAO
;  APPLICANT:  Karen GLATT
;  TITLE OF INVENTION: Nucleic Acid Molecules and Proteins For The Identification,
;  TITLE OF INVENTION:  Assessment, Prevention, and Therapy of Ovarian Cancer
;  FILE REFERENCE: MRI-030
;  CURRENT APPLICATION NUMBER: US/10/097,340
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: 60/276,025
;  PRIOR FILING DATE: 2001-03-14
;  PRIOR APPLICATION NUMBER: 60/325,149
;  PRIOR FILING DATE: 2001-09-26
;  PRIOR APPLICATION NUMBER: 60/276,026
;  PRIOR FILING DATE: 2001-03-14
;  PRIOR APPLICATION NUMBER: 60/324,967
;  PRIOR FILING DATE: 2001/09/26
;  PRIOR APPLICATION NUMBER: 60/311,732
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 60/325,102
;  PRIOR FILING DATE: 2001-09-26
;  PRIOR APPLICATION NUMBER: 60/323,580
;  PRIOR FILING DATE: 2001-09-19
;  NUMBER OF SEQ ID NOS: 363
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 282
;   LENGTH: 176
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-097-340-282

  Query Match             100.0%;  Score 935;  DB 4;  Length 176;
  Best Local Similarity   100.0%;  Pred. No. 4.1e-86;
  Matches  176;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 MSAGGASVPPPPNPAVSFPPPRVTLPAGPDILRTYSGAFVCLEILFGGLVWILVASSNVP 60
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1 MSAGGASVPPPPNPAVSFPPPRVTLPAGPDILRTYSGAFVCLEILFGGLVWILVASSNVP 60

Qy       61 LPLLQGWVMFVSVTAFFFSLLFLGMFLSGMVAQIDANWNFLDFAYHFTVFVFYFGAFLLE 120
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       61 LPLLQGWVMFVSVTAFFFSLLFLGMFLSGMVAQIDANWNFLDFAYHFTVFVFYFGAFLLE 120

Qy      121 AAATSLHDLHCNTTITGQPLLSDNQYNINVAASIFAFMTTACYGCSLGLALRRWRP 176
```

```
            | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       121 AAATSLHDLHCNTTITGQPLLSDNQYNINVAASIFAFMTTACYGCSLGLALRRWRP 176
<!--EndFragment-->
```

```
<!--StartFragment-->RESULT 1
AAE03822
ID   AAE03822 standard; protein; 176 AA.
XX
AC   AAE03822;
XX
DT   15-JUN-2007  (revised)
DT   08-AUG-2001  (first entry)
XX
DE   Human gene 5 encoded secreted protein HETKL27, SEQ ID NO: 68.
XX
KW   Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW   foetal abnormality; developmental abnormality; haematopoietic disorder;
KW   immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW   Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW   psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW   inflammation; neurological disorder; Alzheimer's disease; food additive;
KW   angiogenic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW   pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW   cell culture; chemotaxis; vulnerary; binding partner identification;
KW   gene therapy; BOND_PC; mal, T-cell differentiation protein 2;
KW   MAL proteolipid protein 2;
KW   mal, T-cell differentiation protein 2 [Homo sapiens]; MAL2;
KW   MAL2 proteolipid protein; MAL2 proteolipid protein [Homo sapiens];
KW   mal, T-cell differentiation protein 2, isoform CRA_a;
KW   mal, T-cell differentiation protein 2, isoform CRA_a [Homo sapiens];
KW   Mal, T-cell differentiation protein 2 [Homo sapiens]; MAL2 proteolipid;
KW   MAL2 proteolipid [Homo sapiens]; mal T-cell differentiation protein 2;
KW   mal T-cell differentiation protein 2 [synthetic construct];
KW   mal, T-cell differentiation protein 2 [synthetic construct]; GO5515;
KW   GO16020; GO16021; GO7165; GO7516; GO15267.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .56
FT                   /label= Signal_peptide
FT   Protein         57. .176
FT                   /note= "Mature secreted protein"
XX
PN   WO200136440-A1.
XX
PD   25-MAY-2001.
XX
PF   15-NOV-2000; 2000WO-US031282.
XX
PR   19-NOV-1999;  99US-0166414P.
PR   21-JUL-2000; 2000US-0219665P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Komatsoulis GA,  Birse CE,  Moore PA;
XX
DR   WPI; 2001-343795/36.
DR   N-PSDB; AAD08287.
DR   PC:NCBI; gi16418397.
DR   PC:SWISSPROT; Q969L2.
DR   PC:BIND; 12736,54403,54404.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is used
PT   in preventing, treating or ameliorating a medical condition.
```

```
XX
PS    Claim 11; Fig 1; 553pp; English.
XX
CC    AAD08283-AAD08355 represent cDNAs corresponding to 23 human secreted
CC    protein genes, and AAE03818-AAE03870 represent the proteins they encode.
CC    AAE03871-AAE03896 represent human secreted protein fragments or variants.
CC    The secreted proteins and their genes are useful for preventing, treating
CC    or ameliorating medical conditions, e.g., by protein or gene therapy.
CC    Pathological conditions can be diagnosed by determining the amount of the
CC    new protein in a sample or by determining the presence of mutations in
CC    the new genes. Specific uses are described for each of the 23 genes,
CC    based on the tissues in which they are most highly expressed, and include
CC    developing products for the diagnosis or treatment of proliferative
CC    disorders, cancer, tumours, foetal and developmental abnormalities,
CC    haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC    diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC    neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC    cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC    psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC    angiogenic disorders, kidney disorders, gastrointestinal disorders,
CC    pregnancy-related disorders, endocrine disorders, and infections. The
CC    proteins can also be used to aid wound healing and epithelial cell
CC    proliferation, to prevent skin aging due to sunburn, to maintain organs
CC    before transplantation, for supporting cell culture of primary tissues,
CC    to regenerate tissues, to identify their cognate ligands or binding
CC    partners, and in chemotaxis, and can be used as a food additive or
CC    preservative to modify storage properties. Antibodies specific for a
CC    protein of the invention can be used in alleviating symptoms associated
CC    with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC    radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The
CC    present sequence represents a human secreted protein of the invention
CC
CC    Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC    information from BOND.
XX
SQ    Sequence 176 AA;

  Query Match             100.0%;  Score 935;  DB 4;  Length 176;
  Best Local Similarity   100.0%;  Pred. No. 1.8e-96;
  Matches  176;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy         1 MSAGGASVPPPPNPAVSFPPPRVTLPAGPDILRTYSGAFVCLEILFGGLVWILVASSNVP 60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 MSAGGASVPPPPNPAVSFPPPRVTLPAGPDILRTYSGAFVCLEILFGGLVWILVASSNVP 60

Qy        61 LPLLQGWVMFVSVTAFFFSLLFLGMFLSGMVAQIDANWNFLDFAYHFTVFVFYFGAFLLE 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 LPLLQGWVMFVSVTAFFFSLLFLGMFLSGMVAQIDANWNFLDFAYHFTVFVFYFGAFLLE 120

Qy       121 AAATSLHDLHCNTTITGQPLLSDNQYNINVAASIFAFMTTACYGCSLGLALRRWRP 176
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 AAATSLHDLHCNTTITGQPLLSDNQYNINVAASIFAFMTTACYGCSLGLALRRWRP 176
```

<!--EndFragment-->